Drug Profile
NS 2389
Alternative Names: GW 650250; GW 650250ALatest Information Update: 15 Mar 2002
Price :
$50
*
At a glance
- Originator NeuroSearch
- Developer GlaxoSmithKline
- Class Antidepressants; Butylene glycols
- Mechanism of Action Adrenergic receptor antagonists; Biogenic monoamine uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 15 Mar 2002 Discontinued - Phase-II for Depression in United Kingdom (unspecified route)
- 15 Mar 2002 Discontinued - Phase-II for Depression in USA (unspecified route)
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline